Microfluidic Devices Created from Ordinary, Inexpensive Components
|
By LabMedica International staff writers Posted on 16 Feb 2012 |

Image: NIST scientists combined a glass slide, plastic sheets, and double-sided tape to create an inexpensive and simple-to-build microfluidic device for exposing an array of cells to different concentrations of a chemical (Photo courtesy of Cooksey/NIST).
A glass slide, plastic sheets, and double-sided tape were combined to create a diffusion-based gradient generator, a tool that rapidly assesses how changing concentrations of specific chemicals affect living cells.
Exposing an array of cultured cells to a chemical gradient provides a solution where the chemical concentration changes gradually and predictably across the array. Such gradients are a rapid, high-throughput way to evaluate the effect on cell growth or toxicity.
Created by National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) engineer Javier Atencia the gradient generator is built in layers, with each section precisely positioned with an alignment tab. The base is a glass slide, upon which is attached a strip of double-sided tape cut to have a row of four micrometer-sized channels. On top of this is placed a polystyrene strip cut to have two lines each of four tiny circular "wells" where each pair lines up with the ends of the channel below it. The next layer is another strip of double-sided tape, this time with a Y-shaped canal cut into it to serve as the flow path for the chemical gradient. Finally, a Mylar strip cut to have an identical Y-canal serves as the cover.
The hinged cover allows access to the wells for adding test cells. Once done, the cover is lowered and affixed, sealing the gradient generator. Fluid flow in and out of the system is accomplished using magnetic connectors. Under constant pressure, the flow assures a steady-state stream through the device and creates a diffusion gradient in each buried channel. Cells in the channels are simultaneously exposed to a range of chemical concentrations from high to low.
Conventional microfluidic systems usually mix fluids by pumping them in a circular motion or by twisting and folding them together. The new NIST system's gradient is created by diffusion––the gentle movement of matter from one point to another by random molecular motion. This greatly reduces the risk of cells being swept away or damaged by shearing forces in the test fluid.
The device was tested by loading it with cells genetically engineered to produce large amounts of green fluorescent protein (GFP) and then introduced cycloheximide (CHX), a chemical that shuts down ribosomes, the cell's protein factories. Cells exposed to the toxin quickly stop synthesizing GFP, decreasing fluorescence by an amount directly related to the concentration of CHX.
This is what the scientists observed in the gradient generator assays. The cells were exposed three times to CHX, and each time, the level of GFP fluorescence increased as the concentration of CHX in the gradient decreased, and vice versa.
The new device was described in the 2012 edition of the journal Lab-on-a-Chip.
Related Links:
National Institute of Standards and Technology
Exposing an array of cultured cells to a chemical gradient provides a solution where the chemical concentration changes gradually and predictably across the array. Such gradients are a rapid, high-throughput way to evaluate the effect on cell growth or toxicity.
Created by National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) engineer Javier Atencia the gradient generator is built in layers, with each section precisely positioned with an alignment tab. The base is a glass slide, upon which is attached a strip of double-sided tape cut to have a row of four micrometer-sized channels. On top of this is placed a polystyrene strip cut to have two lines each of four tiny circular "wells" where each pair lines up with the ends of the channel below it. The next layer is another strip of double-sided tape, this time with a Y-shaped canal cut into it to serve as the flow path for the chemical gradient. Finally, a Mylar strip cut to have an identical Y-canal serves as the cover.
The hinged cover allows access to the wells for adding test cells. Once done, the cover is lowered and affixed, sealing the gradient generator. Fluid flow in and out of the system is accomplished using magnetic connectors. Under constant pressure, the flow assures a steady-state stream through the device and creates a diffusion gradient in each buried channel. Cells in the channels are simultaneously exposed to a range of chemical concentrations from high to low.
Conventional microfluidic systems usually mix fluids by pumping them in a circular motion or by twisting and folding them together. The new NIST system's gradient is created by diffusion––the gentle movement of matter from one point to another by random molecular motion. This greatly reduces the risk of cells being swept away or damaged by shearing forces in the test fluid.
The device was tested by loading it with cells genetically engineered to produce large amounts of green fluorescent protein (GFP) and then introduced cycloheximide (CHX), a chemical that shuts down ribosomes, the cell's protein factories. Cells exposed to the toxin quickly stop synthesizing GFP, decreasing fluorescence by an amount directly related to the concentration of CHX.
This is what the scientists observed in the gradient generator assays. The cells were exposed three times to CHX, and each time, the level of GFP fluorescence increased as the concentration of CHX in the gradient decreased, and vice versa.
The new device was described in the 2012 edition of the journal Lab-on-a-Chip.
Related Links:
National Institute of Standards and Technology
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








